Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 247  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission

 Table of Contents  
Year : 2012  |  Volume : 4  |  Issue : 6  |  Page : 252-255  

Antibiotics in the management of aggressive periodontitis

1 Department of Periodontics, JKK Nataraja Dental College and Hospital, Komarapalayam, India
2 Department of Periodontics, Tagore Dental College and Hospital, Vandalur, Chennai, Tamilnadu, India

Date of Submission01-Feb-2011
Date of Decision02-Jan-2012
Date of Acceptance26-Jan-2012
Date of Web Publication28-Aug-2012

Correspondence Address:
Abinaya Prakasam
Department of Periodontics, JKK Nataraja Dental College and Hospital, Komarapalayam
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0975-7406.100226

Rights and Permissions

Aggressive periodontitis, although not rare, is a fairly unknown condition. Little is known about its optimal management. While majority of patients with common forms of periodontal disease respond predictably well to conventional therapy (oral hygiene instructions (OHI), non-surgical debridement, surgery, and Supportive Periodontal therapy (SPT)), patients diagnosed with aggressive form of periodontal disease often do not respond predictably/favorably to conventional therapy owing to its complex multi-factorial etiology. Protocols for treating aggressive periodontitis are largely empirical. There is compelling evidence that adjunctive antibiotic treatment frequently results in more favorable clinical response than conventional therapy alone. This article mainly focuses on the role of adjunct use of pharmacological agents in improving the prognosis and treatment outcome of aggressive periodontitis patients.

Keywords: Antibiotics, aggressive periodontitis, adjunctive use of systemic antibiotics, host modulation

How to cite this article:
Prakasam A, Elavarasu S S, Natarajan RK. Antibiotics in the management of aggressive periodontitis. J Pharm Bioall Sci 2012;4, Suppl S2:252-5

How to cite this URL:
Prakasam A, Elavarasu S S, Natarajan RK. Antibiotics in the management of aggressive periodontitis. J Pharm Bioall Sci [serial online] 2012 [cited 2022 Aug 19];4, Suppl S2:252-5. Available from:

Aggressive periodontitis, by definition, causes rapid destruction of the periodontal attachment apparatus and the supporting alveolar bone. It can present in a localized or generalized form. Two common features of both forms are (1) rapid attachment loss and bone destruction in an otherwise clinically healthy patient and (2) a familial aggregation. [1] These patients often present with limited microbial deposits that seem inconsistent with the severity of tissue destruction. However, the deposits that are present often have elevated levels of Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans, [2] or Porphyromonas gingivalis. These patients may also present with phagocyte abnormalities and a hyperresponsive monocyte/macrophage phenotype. These clinical, microbiological, and immunologic features would suggest that patients diagnosed with aggressive periodontitis would have poor prognosis. The responsiveness of aggressive periodontitis to conventional periodontal treatment is unpredictable, and the overall prognosis for these patients is poorer than for patients with chronic periodontitis.

However, the clinician should consider additional specific features of the localized form of disease when determining the prognosis. Localized aggressive periodontitis usually occurs around the age of puberty and is localized to first molars and incisors. [3] The patient often exhibits a strong serum antibody response to infecting agents, which may contribute to localization of the lesions. When diagnosed early, these can be treated conservatively with OHI and systemic antibiotic therapy, resulting in an excellent prognosis. When more advanced disease occurs, the prognosis can still be good if the lesions are treated with debridement, local and systemic antibiotics, and regenerative therapy. In contrast, patients with generalized form of the disease are also young with generalized interproximal attachment loss and a poor antibody response. Secondary contributing factors such as cigarette smoking are often present. These factors, coupled with alteration in host defense seen in many of these patients, may result in a case that does not respond well to conventional periodontal therapy (scaling with root planing, oral hygiene instruction, and surgical intervention). Therefore, these patients often have a fair, poor, or questionable prognosis, and the use of systemic antibiotics should be considered to help control the disease.

   Antimicrobial Therapy Top

The presence of periodontal pathogens, specifically A. actinomycetemcomitans, has been implicated as the reason that aggressive periodontitis does not respond to conventional therapy alone. These pathogens are known to remain in the tissues [4] after therapy and re-infect the pocket. The identification of A. actinomycetemcomitans as a major culprit and the discovery that this organism penetrates the tissues offered another perspective to the pathogenesis of aggressive periodontitis and offered new hope for therapeutic success, namely antibiotics. The use of systemic antibiotics was thought to be necessary to eliminate pathogenic bacteria from the tissues. [4]

There is compelling evidence that adjunctive antibiotic treatment frequently results in a more favorable clinical response than mechanical therapy alone. Indeed, several authors have reported success in the treatment of aggressive periodontitis using antibiotics as adjuncts to standard therapy.

   Empirical Therapy Versus Microbial Testing Top

The choice of antibiotics can either be empiric or guided by information about the nature of the involved pathogenic microorganism(s) and/or their antibiotic susceptibility profile. Currently, there exists no direct evidence that microbiologic diagnosis and targeted selection of antibiotic regimen provides an additional benefit compared to empiric use. [5] In practice, antibiotics are often used empirically without microbial testing. Studies conducted to evaluate the effectiveness of microbial testing concluded that the usefulness of microbial testing may be limited and that empirical use of antibiotics, such as a combination of amoxicillin and metronidazole, may be more clinically sound and cost effective than bacterial identification and antibiotic-sensitivity testing. The use of such measures can still be considered whenever a case of aggressive periodontitis is not responding or if the destruction continues despite good therapeutic efforts.

   Rationale for Antibiotic Therapy Top

The rationale for pharmacological agents in management of aggressive forms of periodontal disease is eliminating the initiating factors and diseased tissues by conventional therapy and augmenting it with systemic pharmacological agents to eliminate the pathogens left in the tissues. It is to be emphasized, in such cases, that use of antibiotics is as important as the conventional therapy. [6] Mechanical treatment may not predictably eliminate putative pathogens such as A. actinomycetemcomitans from sub-gingival area due to them being inaccessible to mechanical intervention, especially in areas such as root concavities, furcation, and their ability to invade periodontal tissues and dentinal tubules. Persistence in non-dental areas such as dorsum of tongue or tonsils is again an important area of concern.

While the use of antibiotics in periodontal treatment will probably always be controversial, reports from both the American Academy of Periodontology and the European Federation of Periodontology contain valuable guidance for their use. Both these reports, following exhaustive literature searches, determined that patients with aggressive periodontitis appear to benefit from the adjunctive use of systemic antibiotics during treatment.

   Systemic Administration of Antibiotics Top

An ideal antibiotic for use in prevention and treatment of periodontal disease should be specific for periodontal pathogens, allogenic and nontoxic, substantive, not in general use for treatment of other diseases, and inexpensive. [7] Currently, an ideal such antibiotic does not exist. [6] Although oral bacteria are susceptible to many antibiotics, no single antibiotic at concentrations achieved in body fluids inhibits all putative periodontal pathogens. Indeed, it is suggested that a combination of drugs may be necessary to eliminate all putative pathogens from some periodontal pockets.

   Tetracyclines Top

Tetracyclines have been widely used in treating refractory forms of periodontal disease, including localized aggressive periodontitis. They have the ability to concentrate in the periodontal tissues and inhibit the growth of A. actinomycetemcomitans. [8] In addition, they exhibit anti-collagenase effect which can inhibit tissue destruction and aid in bone regeneration. Mechanical removal of calculus and plaque from the root surfaces may not eliminate the bacteria from periodontal tissues. Systemic tetracycline can eliminate tissue bacteria and has been shown to arrest bone loss and suppress microbial levels in conjunction with scaling and root planing. [9] The dosage recommended is 250 mg, 4 times daily (qid).

   Doxycycline Top

The importance of doxycycline arises from the fact that it has higher availability in gingival crevice when compared to other drugs, 7-20 times more than any other drug. [10] The second most important factor is its dual mechanism of action. As an antibiotic agent, it has more significant action against A. actinomycetemcomitans, warranting its use in aggressive periodontitis. [10]

Also, its actions do not limit to antimicrobial activity, but include the following host modulating properties:

  • Anticollagenase
  • Anti-inflammatory
  • Inhibition of bone resorption
  • Promotes reattachment
  • Concept of low dose doxycycline (LDD)
  • Chemically modified tetracycline (CMT).

Because doxycycline can be given only once daily, it makes it more patient compliant. Compliance is also favored because absorption from the GI tract is only slightly altered. The recommended dosage as an anti-infective agent is 100mg bid on the first day, followed with 100mg once daily for 21 days.

   Metronidazole Top

Metronidazole is not the drug of choice for treating A. actinomycetemcomitans infections. However, it is effective against them when used in combination with other antibiotics. [11] It is also effective against anaerobes such as P. gingivalis and Prevotella intermedia. [6] Studies have suggested that when combined with amoxicillin or amoxicillin-clavulanate potassium, metronidazole may be of value in the management of patients with aggressive periodontitis.

   Amoxicillin Top

Amoxicillin is found to be useful in the management of patients with aggressive periodontitis, in both localized and generalized forms. [12] Recommended dosage is 500 mg tid for 8 days. [6]

   Amoxicillin-Clavulanate Potassium Top

The combination of amoxicillin and clavulanate potassium makes the antibiotic resistant to penicillinase enzymes produced by some bacteria. It has been found to be useful in the management of localized form of aggressive periodontitis, [11] and also to arrest alveolar bone loss.

   Ciprofloxacin Top

Ciprofloxacin is active against gram-negative rods, including all facultative and some anaerobic putative periodontal pathogens. Since it demonstrates minimal effect on Streptococcus species, which are associated with periodontal health, its administration may facilitate the establishment of microflora associated with periodontal health. At present, ciprofloxacin is the only antibiotic in periodontal therapy to which all strains of A. actinomycetemcomitans are susceptible. It has also been used in combination with metronidazole. [13]

   Macrolides Top

Azithromycin is found to be effective against anaerobes and gram-negative bacilli. The concentration of azithromycin in tissue specimens from periodontal lesions is significantly higher than that of normal gingiva. [14] It also has been proposed that this drug penetrates fibroblasts and phagocytes, suggesting that it is actively transported to sites of inflammation by phagocytes and then released directly into the sites of inflammation as the phagocytes rupture during phagocytosis. [15]

Recent data suggest that azithromycin can be an effective adjunctive therapy for increasing attachment levels in patients with aggressive periodontitis. Therapeutic dosage is single dose of 250 mg/day for 5 days, after an initial loading dose of 500 mg.

   Serial and Combination Therapy Top

Periodontal infections contain a wide diversity of bacteria; hence, no single antibiotic can be effective against all putative pathogens. [16] This "mixed" infection" can include a variety of aerobic, microaerophilic, and anaerobic bacteria, both gram negative and gram positive. This scenario makes it mandatory to use more than one antibiotic, either serially or in combination. [11]

The metronidazole-amoxicillin and metronidazole-amoxicillin-clavulanate potassium combination caused excellent elimination of many organisms in localized aggressive periodontitis that had been treated unsuccessfully with tetracycline and mechanical debridement. [11] Metronidazole-ciprofloxacin combination is effective against A. actinomycetemcomitans; metronidazole targets obligate anaerobes, and ciprofloxacin targets facultative anaerobes. This is very powerful combination against mixed infections. This combination provides a therapeutic benefit by reducing or eliminating pathogenic microorganisms and offers a prophylactic benefit by giving rise to predominantly streptococcal microflora. [13]

Antibiotics that are bacteriostatic (e.g. tetracycline) generally require rapidly dividing microorganisms to be effective. They do not function well if a bactericidal antibiotic (e.g. amoxicillin) is given concurrently. When both these drugs are required, they are best given serially, not in combination.

   Current Approaches Top

Local delivery

The use of local delivery method to administer antibiotic offers a novel approach to the management of periodontal "localized" infections. The primary advantage is that smaller doses of topical agents can be delivered inside the pocket, avoiding the side effects of systemic antibacterial agents, while increasing the exposure of target microorganisms to higher concentrations and therefore more therapeutic levels of the medication. [17]

Full mouth disinfection

Another approach to antimicrobial therapy in the control of infection associated with periodontitis is the concept of full mouth disinfection. The procedure consists of full mouth debridement completed in two appointments within a 24-h period. In addition to scaling and root planing, the tongue is brushed with chlorhexidine gel (1%) for 1 min, the mouth is rinsed with chlorhexidine solution (0.2%) for 2 min, and periodontal pockets are irrigated with chlorhexidine solution (1%). Significant reduction in pocket depth and gain in clinical attachment in patients with aggressive periodontitis up to 8 months after treatment was noted, and also, significant reduction was found in periodontal pathogens up to 8 months after therapy. [17]

Host modulation

A novel approach in the treatment of aggressive periodontitis is the administration of agents that modulate the host response. The use of sub-antimicrobial dose doxycycline (SDD) [18] may help to prevent the destruction of the periodontal attachment by controlling the activation of matrix metalloproteinases, especially collagenase, from both the infiltrating cells and resident cells of the periodontium, primarily neutrophils. SDD, as an adjunct to repeated mechanical debridement, resulted in clinical improvement in patients with generalized aggressive periodontitis.

Other agents such as CMT, flubiprofen, indomethacin, and naproxen may reduce inflammatory mediator production. Further research is awaited for the use of such agents.

Treatment plan

Treatment of aggressive periodontitis should start with scaling and root planing in combination with systemic antibiotics. It is recommended [19] that (i) initiation of antibiotic therapy is done 24 h before starting scaling and root planing and (ii) the root planing is performed over the short time period during which the antibiotic is prescribed.

A 4-6 week re-evaluation interval seems to be valid for a patient with aggressive periodontitis. If, however, there is no significant response to initial therapy, the clinician may choose to repeat sub-gingival scaling with a different antibiotic regimen. If the response to initial therapy supports proceeding to the surgical phase, systemic antibiotic should be prescribed with the patient being instructed to start taking the antibiotic approximately 1 h before surgery. [20] Chlorhexidine rinses should be prescribed and continued for several weeks to aid healing and augment plaque control.

Periodontal maintenance

Ultimately, the clinician's success in treating patients with aggressive periodontitis depends mostly on the maintenance program. Monthly maintenance is recommended for the first 6 months, after completing active treatment, and then bi-monthly maintenance for six more months. If the patient is stable during this first year, maintenance intervals can be extended up to 3 months. Sub-gingival scaling in combination with local delivery of antibiotics is a good way to manage isolated sites of recurring disease, while full mouth scaling and systemic antibiotics or host modulation therapy can be used to treat a generalized recurrence. [19]

   Conclusion Top

Aggressive periodontitis is a challenge for the clinician because it is infrequently encountered and the predictability of treatment success varies from one patient to another. These unusual entities often do not respond well to conventional therapy owing to the complex nature of the disease. The best treatment for these patients appears to be a combination of conventional treatment with antimicrobial therapy (systemic and/or local delivery) and close follow-up care. Adjunctive host modulation, although only an emerging are of interest, may prove to be promising in the treatment of patients with aggressive periodontitis.

   References Top

1.Hart Tc. Genetic risk factors for esrly-onset periodontitis. J Periodontol 1996;67:355.  Back to cited text no. 1
2.Tonetti MS, Mombelli A. Early onset periodontitis. Annals of Periodontol 1999;4:39.  Back to cited text no. 2
3.Armitage GC, Cullinan MP. Comparison of the clinical features of chronic and aggressive periodontitis. Periodontology 2000, 2010;53:12.  Back to cited text no. 3
4.Christersson LA, Wikesjo UM, Albini B, Zambon JJ, Genco RJ. Tissue localization of Actinobacillus actinomycetemcomitans in human periodontitis. II. Correlation between immunofluorescence and culture techniques. J Periodontol 1987;58:540.  Back to cited text no. 4
5.Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal therapy. A systematic review. Annals of Periodontol 2003;8:115.  Back to cited text no. 5
6.Jorgensen MG, Slots J. Practical antimicrobial periodontal therapy. Compend Contin Educ Dent 2000;21:111.  Back to cited text no. 6
7.Gibson W. Antibiotics and periodontal disease: A selective review of the literature. J Am Dent Assoc 1982;104:213.  Back to cited text no. 7
8.Weinstein L. Antimicrobial agents: Tetracyclines and Chloramphenicol. In: Goodman LS, Gilman A, editors. The Pharmacological Basis of Therapeutics. 5 ed. New York: Macmillan; 1975.  Back to cited text no. 8
9.Gordon Jm. Walker CB, Murphy JC. Concentration of tetracycline in human gingival fluid after single doses. J Clin Periodontol 1981;8:117.  Back to cited text no. 9
10.Slots J, Rams TE. Antibiotics and periodontal therapy: Advantages and disadvantages. J Clin Periodontol 1990;17:479.  Back to cited text no. 10
11.Rams TE, Slots J. Antibiotics in periodontal therapy: An update. Compend Contin Educ Dent 1992;13:1130.  Back to cited text no. 11
12.Weinstein L. Antimicrobial agents: Penicillins and cephalosporins. In: Goodman LS, Gilman A, editors. The Pharmacological Basis of Therapeutics. 5 ed. New York: Macmillan; 1975.  Back to cited text no. 12
13.Rams TE, Feik D, Slots J. Ciprofloxacin/metronidazole treatment of recurrent adult Periodontitis. Abstract. J Dent Res 1992;71:319.  Back to cited text no. 13
14.Malizia T, Tejada MR, Ghelardi E, Senesi S, Gabriele M, Giuca MR, et al. Periodontal tissue disposition of azithromycin. J Periodontol 1997;68:1206.  Back to cited text no. 14
15.Hoepelman IM, Schneider MME. Azithromycin: The first of the tissue selective azalides. Int J Antimicrob Agents 1995;5:145.  Back to cited text no. 15
16.Walker CB, Gordon JM, Magnusson I, Clark WB. A role for antibiotics in the treatment of refractory Periodontitis. J Periodontol 1993;64:772.  Back to cited text no. 16
17.Moriera RM, Feres-Filho EJ. Comparison between full mouth scaling and root planing and quadrant wise basic therapy of aggressive periodontitis: 6 month clinical results. J Periodontol 2007;78:1683.  Back to cited text no. 17
18.Caton J, Bleiden T, Ciancio S. Treatment with Subantimicrobial Dose Doxycycline improves the efficacy of Scaling and Root planing in Patients with Adult Periodontitis. J Periodontol 2000;71:521  Back to cited text no. 18
19.Deas DE, Mealey BL. Response of chronic and aggressive Periodontitis to treatment. Periodontology 2000, 2010;53:154.  Back to cited text no. 19
20.Mealey BL, Klokkevold PR, Corgel JO: Periodontal treatment of Medically Comprimised Patients. Textbook of Carranza's Clinical Periodontology. Ed 9. Elsevier Science 2003;38:527.  Back to cited text no. 20

This article has been cited by
1 Role of nanostructured materials in hard tissue engineering
Ramón Rial, Zhen Liu, Paula Messina, Juan M. Ruso
Advances in Colloid and Interface Science. 2022; 304: 102682
[Pubmed] | [DOI]
2 Meta-Analysis of Two Human RNA-seq Datasets to Determine Periodontitis Diagnostic Biomarkers and Drug Target Candidates
Carlos Moreno, Ellie Bybee, Claudia M. Tellez Freitas, Brett E. Pickett, K. Scott Weber
International Journal of Molecular Sciences. 2022; 23(10): 5580
[Pubmed] | [DOI]
3 Aggregatibacter actinomycetemcomitans as the Aetiological Cause of Rheumatoid Arthritis: What Are the Unsolved Puzzles?
Sung Cheng Looh, Zoey May Pheng Soo, Jia Jia Wong, Hok Chai Yam, Sook Khuan Chow, Jung Shan Hwang
Toxins. 2022; 14(1): 50
[Pubmed] | [DOI]
J Myšák, Š Podzimek, T Janatová, J Dušková, J Janata, L Najmanová
Ceská stomatologie/Praktické zubní lékarství. 2021; 121(3): 67
[Pubmed] | [DOI]
5 Polysaccharide-Based Micro- and Nanosized Drug Delivery Systems for Potential Application in the Pediatric Dentistry
Plamen Katsarov, Maria Shindova, Paolina Lukova, Ani Belcheva, Cédric Delattre, Bissera Pilicheva
Polymers. 2021; 13(19): 3342
[Pubmed] | [DOI]
6 Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment
Lekshmi Narendrakumar, Iype Joseph, Sabu Thomas
Expert Review of Anti-infective Therapy. 2021; 19(8): 1001
[Pubmed] | [DOI]
7 Micellization and gelation characteristics of different blends of pluronic F127/methylcellulose and their use as mucoadhesive in situ gel for periodontitis
Onpreeya Boonrat, Vimon Tantishaiyakul, Namon Hirun
Polymer Bulletin. 2021;
[Pubmed] | [DOI]
8 Immunomodulatory microneedle patch for periodontal tissue regeneration
Xuexiang Zhang, Mohammad Mahdi Hasani-Sadrabadi, Jana Zarubova, Erfan Dashtimighadam, Reihaneh Haghniaz, Ali Khademhosseini, Manish J. Butte, Alireza Moshaverinia, Tara Aghaloo, Song Li
Matter. 2021;
[Pubmed] | [DOI]
9 Cationic Antimicrobial Peptides Are Leading the Way to Combat Oropathogenic Infections
Bruce Lin, Rong Li, Thomas N.G. Handley, John D. Wade, Wenyi Li, Neil M. O’Brien-Simpson
ACS Infectious Diseases. 2021; 7(11): 2959
[Pubmed] | [DOI]
10 Porphyromonas gingivalis: where do we stand in our battle against this oral pathogen?
Kaitlind C. Howard, Octavio A. Gonzalez, Sylvie Garneau-Tsodikova
RSC Medicinal Chemistry. 2021; 12(5): 666
[Pubmed] | [DOI]
11 Sponges containing tetracycline loaded-PLGA-zein microparticles as a periodontal controlled release device
Francisco F.O. Sousa, Asteria Luzardo-Álvarez, Antonio Pérez-Estévéz, Rafael Seoane-Prado, José Blanco-Méndez
Journal of Drug Delivery Science and Technology. 2020; 59: 101858
[Pubmed] | [DOI]
12 Wheat germ agglutinin liposomes with surface grafted cyclodextrins as bioadhesive dual-drug delivery nanocarriers to treat oral cells
Sashini S. Wijetunge, Jianchuan Wen, Chih-Ko Yeh, Yuyu Sun
Colloids and Surfaces B: Biointerfaces. 2020; 185: 110572
[Pubmed] | [DOI]
13 Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics
Eric Krueger, Angela C. Brown
Molecular Oral Microbiology. 2020; 35(3): 85
[Pubmed] | [DOI]
14 Topical antibiotic therapy in periodontology
L. Yu. Orekhova, E. S. Loboda, E. V. Kosova, V. Yu. Vashneva, A. A. Petrov
Parodontologiya. 2020; 25(3): 217
[Pubmed] | [DOI]
15 Impact of PCL nanofiber mat structural properties on hydrophilic drug release and antibacterial activity on periodontal pathogens
Špela Zupancic, Liis Preem, Julijana Kristl, Marta Putrinš, Tanel Tenson, Petra Kocbek, Karin Kogermann
European Journal of Pharmaceutical Sciences. 2018; 122: 347
[Pubmed] | [DOI]
16 Repurposing AM404 for the treatment of oral infections by Porphyromonas gingivalis
Evelien Gerits,Pieter Spincemaille,Kaat De Cremer,Katrijn De Brucker,Serge Beullens,Karin Thevissen,Bruno P.A. Cammue,Katleen Vandamme,Maarten Fauvart,Natalie Verstraeten,Jan Michiels
Clinical and Experimental Dental Research. 2017; 3(2): 69
[Pubmed] | [DOI]
17 A 15-amino acid C-terminal peptide of beta-defensin-3 inhibits bone resorption by inhibiting the osteoclast differentiation and disrupting podosome belt formation
Ok-Jin Park,Jiseon Kim,Ki Bum Ahn,Jue Yeon Lee,Yoon-Jeong Park,Kee-Yeon Kum,Cheol-Heui Yun,Seung Hyun Han
Journal of Molecular Medicine. 2017;
[Pubmed] | [DOI]
18 Patterns of drugs prescribed for dental outpatients in Nigeria: findings and implications
Joseph O. Fadare,Kazeem A. Oshikoya,Obitade S. Obimakinde,Abayomi O. Sijuade,Jide M. Afolayan,Adeyinka A. Adeleke,Brian Godman,Damilola O. Ojumu
Acta Odontologica Scandinavica. 2017; : 1
[Pubmed] | [DOI]
19 Manejo de las infecciones odontogénicas en las consultas de atención primaria: żantibiótico?
Purificación Robles Raya,Ana Pilar Javierre Miranda,Nemesio Moreno Millán,Ariadna Mas Casals,Elena de Frutos Echániz,M. Luisa Morató Agustí
Atención Primaria. 2017;
[Pubmed] | [DOI]
20 New approaches to combat Porphyromonas gingivalis biofilms
Evelien Gerits,Natalie Verstraeten,Jan Michiels
Journal of Oral Microbiology. 2017; 9(1): 1300366
[Pubmed] | [DOI]
21 Drug loaded poly(glycerol sebacate) as a local drug delivery system for the treatment of periodontal disease
Bo Yang,Wei Lv,Ying Deng
RSC Adv.. 2017; 7(59): 37426
[Pubmed] | [DOI]
22 Aggregatibacter Actinomycetemcomitans-Induced Aim2 Inflammasome Activation is Suppressed by Xylitol in Differentiated Thp-1 Macrophages
Seyeon Kim,Mi Hee Park,Yu-Ri Song,Hee Sam Na,Jin Chung
Journal of Periodontology. 2016; : 1
[Pubmed] | [DOI]
23 Efficacy assessment of local doxycycline treatment in periodontal patients using multivariate chemometric approach
Liljana Bogdanovska,Ana Poceva Panovska,Natalija Nakov,Marija Zafirova,Mirjana Popovska,Aneta Dimitrovska,Rumenka Petkovska
European Journal of Pharmaceutical Sciences. 2016; 91: 114
[Pubmed] | [DOI]
24 Local delivery system of doxycycline hyclate based on ?-caprolactone copolymers for periodontitis treatment
Anna Kopytynska-Kasperczyk,Piotr Dobrzynski,Malgorzata Pastusiak,Bozena Jarzabek,Wojciech Prochwicz
International Journal of Pharmaceutics. 2015; 491(1-2): 335
[Pubmed] | [DOI]
25 Functionalised nanoscale coatings using layer-by-layer assembly for imparting antibacterial properties to polylactide-co-glycolide surfaces
Piergiorgio Gentile,Maria E. Frongia,Mar Cardellach,Cheryl A. Miller,Graham P. Stafford,Graham J. Leggett,Paul V. Hatton
Acta Biomaterialia. 2015; 21: 35
[Pubmed] | [DOI]
26 16S rRNA based microarray analysis of ten periodontal bacteria in patients with different forms of periodontitis
Nursen Topcuoglu,Guven Kulekci
Anaerobe. 2015; 35: 35
[Pubmed] | [DOI]
27 Mucoadhesive gel containing immunotherapeutic nanoparticulate satranidazole for treatment of periodontitis: development and its clinical implications
Yuvraj Singh,Parameswara R. Vuddanda,Achint Jain,Sarita Parihar,Thakur P. Chaturvedi,Sanjay Singh
RSC Adv.. 2015; 5(59): 47659
[Pubmed] | [DOI]
28 Outcome of single immediate implants placed in post-extraction infected and non-infected sites, restored with cemented crowns: A 3-year prospective study
Carlos Torres-Sánchez,Raquel Castillo-Oyagüe,Vanesa Montoya-Salazar,Christopher D. Lynch,José-Luis Gutiérrez-Pérez,Daniel Torres-Lagares
Journal of Dentistry. 2014;
[Pubmed] | [DOI]
29 Periodontology: Antibiotics protocol
A. Dziedzic,R. D. Wojtyczka
BDJ. 2014; 217(12): 660
[Pubmed] | [DOI]
30 Using Risk Assessment in Periodontics
Alan J Woodman
Primary Dental Journal. 2014; 3(3): 51
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Antimicrobial Th...
    Empirical Therap...
    Rationale for An...
    Systemic Adminis...
    Serial and Combi...
   Current Approaches

 Article Access Statistics
    PDF Downloaded473    
    Comments [Add]    
    Cited by others 30    

Recommend this journal